14. Composition according to any one of claims 1 to 13 for use in the treatment of nausea, muscular spasm, multiple sclerosis, uterine and bowel cramps, movement disorders, pain, including migraine headache, glaucoma, asthma, inflammation, insomnia, high blood pressure and/or a condition responsive to an appetite stimulating, amyotrophic lateral sclerosis, anti-cancer, oxytoxic, anxiolytic, anti-convulsive, anti-depressant and anti-psychotic agent.

15. Method for producing a complex of RAMEB and Nabilone according to any one of claims 1 to 14, wherein said RAMEB is combined with Nabilone in a heterogeneous state or in the solid state, including using methods selected from freeze drying, spray-drying, kneading, grinding, slurry-method, co-precipitation, and neutralization, and optionally separating the obtained complex.

16. Method for producing aqueous soluble Nabilone according to claim 15 comprising the step of complexing Nabilone with RAMEB.

17. Method for increasing the bioavailability of Nabilone in a sublingually or buccally administered preparation comprising the step of complexing Nabilone with RAMEB according to any one of claims 15 and 16, and formulating the complex obtained as a sublingually or buccally administerable dosage form.

18. Method for increasing the solubility of the Nabilone in aqueous solution by complexing Nabilone and RAMEB wherein Nabilone is stirred for about 96 h in the presence of 25% or 30 weight % RAMEB and maintaining a constant reaction temperature of about 25°C.

19. Composition according to any one of claims 1 to 11 comprising between 10 and 15 wt%, preferably about 11.5 wt% Nabilone-RAMEB complex, between 60 and 95 wt%, preferably about 87.5 wt%, disintegrating agent and between 0.5 and 5 wt%, preferably about 1 wt% pharmaceutically acceptable carrier.